$MED
MEDIFAST INC

2022 Q4 Form 10-Q Financial Statement

#000162828022028255 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $337.2M $390.4M
YoY Change -10.74% -5.56%
Cost Of Revenue $103.6M $107.5M
YoY Change 4.12% 1.14%
Gross Profit $233.6M $282.8M
YoY Change -16.06% -7.88%
Gross Profit Margin 69.27% 72.45%
Selling, General & Admin $199.8M $234.7M
YoY Change -13.26% -6.83%
% of Gross Profit 85.53% 82.97%
Research & Development $1.200M $1.100M
YoY Change 9.09% -8.33%
% of Gross Profit 0.51% 0.39%
Depreciation & Amortization $2.954M $2.850M
YoY Change -738.01% 8.16%
% of Gross Profit 1.26% 1.01%
Operating Expenses $201.0M $234.7M
YoY Change -13.16% -6.83%
Operating Profit $32.60M $48.16M
YoY Change -30.4% -12.72%
Interest Expense -$182.0K -$261.0K
YoY Change 95.7% 177.66%
% of Operating Profit -0.56% -0.54%
Other Income/Expense, Net -$9.000K -$278.0K
YoY Change -228.57% -1423.81%
Pretax Income $32.41M $47.88M
YoY Change -30.68% -13.25%
Income Tax $5.890M $11.72M
% Of Pretax Income 18.17% 24.49%
Net Earnings $26.52M $36.16M
YoY Change -22.06% -13.88%
Net Earnings / Revenue 7.86% 9.26%
Basic Earnings Per Share $3.30
Diluted Earnings Per Share $2.41 $3.27
COMMON SHARES
Basic Shares Outstanding 10.93M shares 11.02M shares
Diluted Shares Outstanding 11.04M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $87.69M $139.4M
YoY Change -58.97% -55.66%
Cash & Equivalents $87.69M $69.71M
Short-Term Investments $0.00 $69.71M
Other Short-Term Assets $16.24M $14.45M
YoY Change -0.59% 25.16%
Inventory $118.9M $145.3M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $222.8M $229.6M
YoY Change -27.4% -23.74%
LONG-TERM ASSETS
Property, Plant & Equipment $57.19M $58.11M
YoY Change 1.88% 25.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.46M $12.69M
YoY Change 92.58% 97.1%
Total Long-Term Assets $93.43M $96.77M
YoY Change 2.15% 37.61%
TOTAL ASSETS
Total Short-Term Assets $222.8M $229.6M
Total Long-Term Assets $93.43M $96.77M
Total Assets $316.2M $326.4M
YoY Change -20.61% -12.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $134.7M $148.1M
YoY Change -17.52% -4.74%
Accrued Expenses $5.776M $6.126M
YoY Change -11.45% 13.4%
Deferred Revenue $7.357M
YoY Change -8.61%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $140.9M $154.3M
YoY Change -17.04% -4.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.28M $21.57M
YoY Change -22.08% 51.71%
Total Long-Term Liabilities $20.28M $21.57M
YoY Change -22.08% 51.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $140.9M $154.3M
Total Long-Term Liabilities $20.28M $21.57M
Total Liabilities $161.2M $175.8M
YoY Change -17.71% 0.4%
SHAREHOLDERS EQUITY
Retained Earnings $139.9M $131.5M
YoY Change -26.52% -28.2%
Common Stock $11.00K $11.00K
YoY Change -8.33% -8.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $155.0M $150.5M
YoY Change
Total Liabilities & Shareholders Equity $316.2M $326.4M
YoY Change -20.61% -12.12%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $26.52M $36.16M
YoY Change -22.06% -13.88%
Depreciation, Depletion And Amortization $2.954M $2.850M
YoY Change -738.01% 8.16%
Cash From Operating Activities $51.74M $55.40M
YoY Change -793.65% 250.61%
INVESTING ACTIVITIES
Capital Expenditures $9.064M -$1.768M
YoY Change -177.98% -82.98%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$9.064M -$1.768M
YoY Change -22.02% -82.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -24.33M -45.11M
YoY Change -22.1% 5.03%
NET CHANGE
Cash From Operating Activities 51.74M 55.40M
Cash From Investing Activities -9.064M -1.768M
Cash From Financing Activities -24.33M -45.11M
Net Change In Cash 18.34M 8.522M
YoY Change -136.46% -122.7%
FREE CASH FLOW
Cash From Operating Activities $51.74M $55.40M
Capital Expenditures $9.064M -$1.768M
Free Cash Flow $42.68M $57.16M
YoY Change 924.61% 118.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000910329
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31573
dei Entity Registrant Name
EntityRegistrantName
Medifast, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3714405
dei Entity Address Address Line1
EntityAddressAddressLine1
100 International Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Baltimore
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
21202
dei City Area Code
CityAreaCode
410
dei Local Phone Number
LocalPhoneNumber
581-8042
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
MED
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10926989 shares
CY2022Q3 us-gaap Revenues
Revenues
390398000 usd
CY2021Q3 us-gaap Revenues
Revenues
413395000 usd
us-gaap Revenues
Revenues
1261332000 usd
us-gaap Revenues
Revenues
1148253000 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
107549000 usd
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
106338000 usd
us-gaap Cost Of Revenue
CostOfRevenue
354515000 usd
us-gaap Cost Of Revenue
CostOfRevenue
298942000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
282849000 usd
CY2021Q3 us-gaap Gross Profit
GrossProfit
307057000 usd
us-gaap Gross Profit
GrossProfit
906817000 usd
us-gaap Gross Profit
GrossProfit
849311000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
234693000 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
251886000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
754610000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
679907000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
48156000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
55171000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
152207000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
169404000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-261000 usd
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-94000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-519000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-138000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
115000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
112000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-278000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-556000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
47878000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
55192000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
151651000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
169378000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11723000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13210000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34601000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39370000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
36155000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
41982000 usd
us-gaap Net Income Loss
NetIncomeLoss
117050000 usd
us-gaap Net Income Loss
NetIncomeLoss
130008000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.30
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
10.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
11.07
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.27
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
10.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
10.98
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10964000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11692000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11290000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11739000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11042000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11785000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11369000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11840000 shares
CY2022Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.64
CY2021Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.42
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
4.92
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
4.26
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
36155000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
41982000 usd
us-gaap Net Income Loss
NetIncomeLoss
117050000 usd
us-gaap Net Income Loss
NetIncomeLoss
130008000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
123000 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
63000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
300000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
130000 usd
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-16000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-21000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-49000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
123000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
47000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
279000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
81000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
36278000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
42029000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
117329000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
130089000 usd
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69710000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104183000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
145279000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
180043000 usd
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
0 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
5361000 usd
CY2022Q3 us-gaap Prepaid Taxes
PrepaidTaxes
150000 usd
CY2021Q4 us-gaap Prepaid Taxes
PrepaidTaxes
945000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14445000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16334000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
229584000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
306866000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58107000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56131000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19819000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24457000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12691000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6468000 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
6150000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4404000 usd
CY2022Q3 us-gaap Assets
Assets
326351000 usd
CY2021Q4 us-gaap Assets
Assets
398326000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
148129000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
163309000 usd
CY2022Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0 usd
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6126000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6523000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
154255000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
169832000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21574000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26020000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
175829000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
195852000 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
-795000 usd
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10929000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11594000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10928000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11593000 shares
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
11000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
12000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18617000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12018000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
391000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
111000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
131503000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
190333000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
150522000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
202474000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
326351000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
398326000 usd
us-gaap Net Income Loss
NetIncomeLoss
117050000 usd
us-gaap Net Income Loss
NetIncomeLoss
130008000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8026000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3767000 usd
med Operating Lease Expense Non Cash
OperatingLeaseExpenseNonCash
4740000 usd
med Operating Lease Expense Non Cash
OperatingLeaseExpenseNonCash
3508000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8103000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6613000 usd
med Amortization Of Premium On Investment Securities
AmortizationOfPremiumOnInvestmentSecurities
14000 usd
med Amortization Of Premium On Investment Securities
AmortizationOfPremiumOnInvestmentSecurities
70000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1746000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-34764000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
76222000 usd
us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1889000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5094000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
8545000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3393000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-22259000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
42747000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
142831000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
102004000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
5267000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
5145000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7617000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22585000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2350000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17440000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
811000 usd
us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
1504000 usd
us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
1867000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
53698000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
46845000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
120048000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
46000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-175250000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-93901000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
296000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-34473000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9207000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104183000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163723000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69710000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154516000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
33906000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
41302000 usd
us-gaap Dividends Cash
DividendsCash
19395000 usd
us-gaap Dividends Cash
DividendsCash
17351000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
202474000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
41781000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
2275000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1459000 usd
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
10000000 usd
CY2022Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
0 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
16000 usd
CY2022Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
19063000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
216024000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
39113000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
2865000 usd
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
20000 usd
CY2022Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
90038000 usd
CY2022Q2 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
1000 usd
CY2022Q2 med Adjustments To Paid In Capital Share Repurchases Not Yet Settled
AdjustmentsToPaidInCapitalShareRepurchasesNotYetSettled
20010000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
141000 usd
CY2022Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
18598000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
129476000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
36155000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
2963000 usd
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
25000 usd
CY2022Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
20010000 usd
CY2022Q3 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
0 usd
CY2022Q3 us-gaap Accelerated Share Repurchase Program Adjustment
AcceleratedShareRepurchaseProgramAdjustment
20010000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
123000 usd
CY2022Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
18170000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
150522000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
157246000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
41063000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
2198000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
481000 usd
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1807000 usd
CY2021Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
7500000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
62000 usd
CY2021Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
16852000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
174891000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
46963000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
1839000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
221000 usd
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
26000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-28000 usd
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
12230000 usd
CY2021Q2 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
0 usd
CY2021Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
16941000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
194689000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
41982000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
2269000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
109000 usd
CY2021Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
34000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
47000 usd
CY2021Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
26270000 usd
CY2021Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
16553000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
196239000 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the condensed consolidated financial statements had a material impact on the presentation.</span>
us-gaap Use Of Estimates
UseOfEstimates
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span>
CY2022Q3 us-gaap Noncash Contribution Expense
NoncashContributionExpense
1100000 usd
us-gaap Noncash Contribution Expense
NoncashContributionExpense
10500000 usd
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
11989000 usd
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
15196000 usd
CY2022Q3 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
3078000 usd
CY2021Q4 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
3641000 usd
CY2022Q3 med Inventory Non Food Finished Goods
InventoryNonFoodFinishedGoods
10455000 usd
CY2021Q4 med Inventory Non Food Finished Goods
InventoryNonFoodFinishedGoods
15991000 usd
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
122227000 usd
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
152687000 usd
CY2022Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2470000 usd
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7472000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
145279000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
180043000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
36155000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
41982000 usd
us-gaap Net Income Loss
NetIncomeLoss
117050000 usd
us-gaap Net Income Loss
NetIncomeLoss
130008000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10964000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11692000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11290000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11739000 shares
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
78000 shares
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
93000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
79000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
101000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11042000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11785000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11369000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11840000 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.30
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
10.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
11.07
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.27
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
10.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
10.98
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
26.52
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
66.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
33000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
54.98
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1500000 usd
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
61000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.19
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
49.69
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
33000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
54.98
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
45000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
47.66
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
28000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
52.76
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
35000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
42.00
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P55M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1800000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P53M
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
800000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3300000 usd
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
8000 shares
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
7000 shares
CY2022Q3 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
156000 shares
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2963000 usd
CY2021Q3 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
145000 shares
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2269000 usd
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
156000 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8103000 usd
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
145000 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6613000 usd
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000 usd
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
5200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
3800000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
5413000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
3175000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
103000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9745000 usd
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P60M
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.021
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1787000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6241000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5693000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5825000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4160000 usd
CY2022Q3 med Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
5412000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
29118000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1418000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
27700000 usd
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
69710000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
CY2022Q3 us-gaap Interest Receivable
InterestReceivable
0 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
69710000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69710000 usd
CY2022Q3 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
0 usd
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
109464000 usd
CY2021 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
21000 usd
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
59000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
109544000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104183000 usd
CY2021Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
5361000 usd
CY2022Q3 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0 usd
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
-200000 usd
CY2021Q3 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0 usd
us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0 usd
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
100000000 usd
CY2022Q2 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
480000 shares
CY2022Q3 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
91000 shares

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001628280-22-028255-index-headers.html Edgar Link pending
0001628280-22-028255-index.html Edgar Link pending
0001628280-22-028255.txt Edgar Link pending
0001628280-22-028255-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
med-20220930.htm Edgar Link pending
med-20220930.xsd Edgar Link pending
med-20220930xexx311.htm Edgar Link pending
med-20220930xexx312.htm Edgar Link pending
med-20220930xexx321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
med-20220930_cal.xml Edgar Link unprocessable
med-20220930_def.xml Edgar Link unprocessable
med-20220930_lab.xml Edgar Link unprocessable
med-20220930_pre.xml Edgar Link unprocessable
med-20220930_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending